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Abstract
Objective
To determine whether hypothalamus-pituitary-adrenal axis (HPAA) dysfunction is pro-
spectively associated with global cognitive impairment in later life.
Methods
This cross-cohort study integrates 2 large longitudinal datasets, Whitehall II and the National
Survey for Health and Development (NSHD), on data collected in the Whitehall II study
between 2002–2004, 2007–2009, and 2012–2013; and for NSHD between 2006–2010 and in
2015. Serial salivary cortisol samples were collected multiple times within a 24-hour period at
mean ages 61.2 and 65.9 years in Whitehall II and at age 60–64 years from NSHD participants.
Cortisol proﬁle is deﬁned using cortisol awakening response and AM:PM ratio. Cognitive
function was measured using the Mini-Mental State Examination in Whitehall II and Adden-
brooke’s Cognitive Examination, third version, in NSHD, harmonized into a 30-point score.
Models were adjusted for age, sex, diagnoses of hypertension and diabetes, body mass index
(BMI), educational attainment, and interval between HPAA and cognitive assessments.
Results
In fully adjusted models, increased AM:PM cortisol ratio was prospectively associated with better
later-life cognitive function years later (0.02 fewer errors per SD increase in AM:PM cortisol ratio,
p < 0.01) and verbal ﬂuency (0.03 SD increase in verbal ﬂuency per SD increase in AM:PM ratio,
p < 0.01). Increasing age, lower educational attainment, diagnosis of hypertension, diagnosis of
diabetes, and increased BMI were associated with worse cognitive function and poorer verbal
ﬂuency. There were no associations between depression and later-life cognition or reverse
associations between cognition and later-life cortisol proﬁles.
Conclusions
Loss of diurnal HPAA variation is evident in individuals subsequently experiencing more
cognitive impairment. It may serve as an early preclinical marker of cognitive decline.
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The hypothalamus-pituitary-adrenal axis (HPAA) is a major
component of the physiologic stress response and known to
mediate adaptive changes in brain function, notably memory,
learning, and mood.1 Various strands of evidence have impli-
cated the HPAA in the development and progression of cog-
nitive impairment, though the precise nature of this relationship
is unclear and may be bidirectional: the hypothalamus is regu-
lated though projections from the hippocampus and the limbic
system2—exactly those areas vulnerable to cognitive impair-
ment common in preclinical or early Alzheimer pathology.
Individuals with neurodegeneration can demonstrate higher
baseline plasma3 and CSF cortisol,4 as well as prolonged
elevation of cortisol after an acute phase response.5,6 Cross-
sectional neuroimaging studies have reported HPAA dys-
function to be associated with smaller hippocampal7–9 and
reduced global brain volumes.10 Yet some longitudinal
studies have found no association between cognition and
peak cortisol11 or diurnal variation.12
Diﬀerent cortisol measures are thought to have speciﬁc bi-
ological signiﬁcance: for example, cortisol awakening response
(CAR) has been associated with spatial memory and antici-
pation of cognitive demands,13 while blunted diurnal variation
has been linked to reduced synaptic plasticity14 and hypothe-
sized to be a global negative health proﬁle marker.15 However,
few population studies have proﬁled diurnal HPAA activity due
to challenges of collecting serial cortisol measurements over 24
hours. Using serial measures of salivary cortisol in 2 population
studies, we set out to answer the following question: Is HPAA
dysfunction longitudinally associated with later-life global
cognitive impairment and if so, is one cortisol measure spe-
ciﬁcally associated with cognitive impairment at follow-up?
Methods
Cohorts
This analysis integrates datasets from 2 longitudinal cohorts:
the Whitehall II and National Survey for Health and De-
velopment (NSHD) studies (ﬁgure 1). The Whitehall II study
is an ongoing study of men and women, originally employed by
the British civil service, aged between 35 and 55 years and based
in its London oﬃce (6,895 men and 3,413 women, response
rate 73%) at recruitment to the study in 1985–1988.16 Since
the initial medical examination, follow-up examinations have
continued approximately every 5 years, with each wave taking 2
years to complete. This study obtained Whitehall II data from
2002–2004 (n = 6,967), 2007–2009 (n = 6,761), and
2012–2013 (n = 6,318).
The NSHD is the oldest British birth cohort study, following
a sample of 5,362 male and female participants born in 1 week
in March 1946.17 Between 2006 and 2010, when study
members were aged between 60 and 64 years, 2,229 partic-
ipants out of the 2,856 invited (78%) underwent clinical as-
sessment at a clinical research facility (n = 1,690) or their own
homes during a visit by a research nurse (n = 539). Of the
remaining original participants, 778 had died, 570 were living
abroad, 594 had previously withdrawn from the study, and
564 were lost to follow-up.
Cognitive assessments
In Whitehall II, the Mini-Mental State Examination (MMSE)
was administered at the 2007–2009 (mean age 65.9 years)18
and 2012–2013 (mean age 69.7 years)19 waves of data col-
lection. In addition, participants were asked to generate in
writing as many words beginning with S (phonemic ﬂuency)
and as many animal names (semantic ﬂuency) as they could.
One minute was allowed for each test; the observed range on
these tests was 0–35.
In NSHD, when participants were 69 years of age, cognition
was assessed in 2,149 participants using Addenbrooke’s Cog-
nitive Examination, third version (ACE-III), with a total score
of 100, divided into 5 domains: attention and orientation
(scored 0–18), verbal ﬂuency (0–14), memory (0–26), lan-
guage (0–26), and visuospatial function (0–16). A customized
version of the ACE-III was administered by iPad using ACE
Mobile (acemobile.org/): 32 refused or were unable to un-
dertake the ACE-III; 35 did not have fully completed ACE-III
scores; 353 scores were lost through equipment failure.
Complete ACE-III data were available for 1,729 participants
(80.5% of those who received home visit).20 From the ACE-III
score, a 30-point scale directly comparable to the MMSE score
was extracted in order to harmonize cognitive measures with
the Whitehall II study. In addition, verbal memory and visual
search speed were assessed earlier, when participants were 53
years old; these were taken to be measures of baseline cognitive
function prior to the wave ﬁrst measuring cortisol (see below).
While phonemic ﬂuency was assessed in writing by Whitehall
II, participants in NSHD were verbally asked to name the
words aloud. The 2 ﬂuency scores were then standardized
across individual cohort distributions. The raw scores and
distributions are available online for each wave of both
Whitehall II and NSHD (table e-1, doi.org/10.5061/dryad.
vb3g6p1).
Cortisol measures
Salivary cortisol samples were obtained at a mean age of 61.2
and 65.9 years in Whitehall II and at age 60–64 years from
Glossary
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NSHD participants (ﬁgure 1). Prior to the sample collection,
participants were asked to avoid brushing or ﬂossing their teeth
and eating, drinking, or smoking for 30minutes before. Salivary
cortisol was collected using a Salivette swab. Whitehall II par-
ticipants were asked to provide a total of 6 saliva samples: on
waking; at 30 minutes, 2.5 hours, 8 hours, and 12 hours after
waking; and at bedtime. NSHD participants were asked to
provide 4 saliva samples within 24 hours: during their clinic
appointment, in the subsequent evening between 9 PM and 9:
30 PM on the same day as their clinic appointment, on waking
the following day, and 30 minutes after waking. Participants
were asked to refrigerate the swab before posting the sample to
the laboratory in a protected container. A booklet was used for
participants to record information on the day of sampling in-
cluding date of collection, wake time, and time each sample was
taken. Salivary cortisol levels were measured using a commer-
cial immunoassay with chemiluminescence detection (CLIA;
IBL-Hamburg, Germany). The limit of detection was 0.44
nmol/L; intra-assay and interassay coeﬃcients of variance were
less than 8%. Any sample greater than 50 nmol/Lwas repeated.
Consistent with previous analyses, anomalous salivary proﬁles
were excluded21,22: these included use of corticosteroid medi-
cations, timing of collections suggestive of shift work patterns
(morning sample taken before 4 AM or after midday; evening
sample taken before 8 PM), lack of sample collection timings,
incorrect chronological order of sample timings, or any cortisol
concentration more than 3 SD from the mean.
Covariates
Hypertension was deﬁned as a diagnosis of hypertension,
regular prescription of an antihypertensive, or systolic blood
pressure greater than 140 mm Hg or diastolic blood pressure
greater than 90 mmHg (taken from 2 readings). Diabetes was
deﬁned as participant-reported doctor-diagnosed type 1 or 2
diabetes mellitus, fasting glucose 7.0 mmol/L, a 2-hour post-
load glucose 11.1 mmol/L, or use of diabetes medication.
Height and weight were measured by standardized protocols,
and body mass index (BMI) was calculated (kg/m2). Edu-
cational attainment was deﬁned as highest qualiﬁcation on
leaving full-time education in Whitehall II participants and by
age 26 in NSHD participants. Depression caseness was de-
ﬁned using the General Health Questionnaire to ascertain
depression symptoms, as previous operationalized by Gold-
berg and Hillier23 and within the NSHD cohort by James
et al.24: scores of 5 or over (with the Likert scale recoded to 0-
0-1-1 for each item before summing) were used as the
threshold. For NSHD, covariates were taken from data col-
lection at 60–64 years, the only wave with available cortisol
measures available. For Whitehall II, covariates were taken
from the data collection wave with the second cortisol as-
sessment (2007–2009), when the 2 cohorts were at compa-
rable ages, and any missing covariate data were updated from
the earlier cortisol assessment if available.
Statistical analysis
Global cognitive state was measured on a 30-point scale
(MMSE inWhitehall II; comparable scale extracted from 100-
point ACE-III in NSHD). Given that the distribution of the
MMSE is negatively skewed, it is often transformed using
log(31 − MMSE score).25 Two cortisol measures were de-
rived: (1) CAR, calculated by peak cortisol minus cortisol on
waking; (2) diurnal variation as deﬁned by AM:PM ratio, cal-
culated by the peak cortisol divided by the sample taken latest
in the day (sample 6 in Whitehall II, sample 4 in NSHD). In
order to compare exposures directly, continuous measures
(verbal ﬂuency scores, CAR, log-transformed AM:PM ratios)
were standardized to have a mean of 0 and SD of 1. Covariates
were operationalized as hypertension (yes/no), diabetes
(yes/no), BMI (continuous), and educational attainment
(<O levels, O levels, A levels).
Figure 1 Data collection from Whitehall II and National Survey for Health and Development (NSHD)
ACE-III = Addenbrooke’s Cognitive
Examination, third version; BMI =
body mass index; MMSE = Mini-
Mental State Examination.
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Linear regression was used to estimate the longitudinal as-
sociation of cortisol measures with later-life cognitive per-
formance, years after the cortisol collection. The model was
lagged such that the cortisol measure in the model was from
one data collection wave prior to the cognitive measure and all
estimates were adjusted by follow-up interval. Covariates used
were from the 2007–2009 wave of Whitehall II and ages
60–64 of NSHD using complete cases. Models were also
estimated using multiple imputation for missing covariates
(20 datasets obtained through chained equations using the mi
impute command in Stata). Univariate analyses were ﬁrst
performed between cognition with each cortisol measure and
covariate, followed by a fully adjusted model. All data col-
lected from Whitehall II from the same participant over
multiple waves were clustered by participant. Finally, the same
models were repeated with reversed outcomes and exposures,
with cortisol measures as outcomes and cognitive measures as
lagged exposures. Stata version 14.1 (StataCorp, College
Station, TX) was used for all analyses.
Data availability
Bona ﬁde researchers can apply to access theWhitehall II data
and NSHD data via a standard application procedure. Dei-
dentiﬁed patient data are available for sharing with any other
bona ﬁde researcher for high-quality research output. In-
dividual level and aggregate data are available from Whitehall
II across 12 phases of data collection beginning in 1985. Ag-
gregate data are available for NSHD across 24 waves of data
collection beginning in 1946. All data sharing must be within
the bounds of consent given previously by studymembers and
meet rigorous data security standards, adhering to the core
principles of ethical, equitable, and eﬃcient data sharing as set
out by the Medical Research Council (UK) and subject to
a data sharing agreement. Applications for data sharing can be
made via established protocols as outlined by Medical Re-
search Council Unit of Lifelong Health and Ageing at UCL
(nshd.mrc.ac.uk/data/data-sharing/) and Whitehall II (ucl.
ac.uk/iehc/research/epidemiology-public-health/research/
whitehallII/data-sharing).
Results
The mean ages of participants from the 3 waves of Whitehall
data at 2002–2004, 2007–2009, and 2012–2013 were 61,
65.8, and 63.3 years, respectively (table 1). Women in both
cohorts demonstrated a greater CAR; men demonstrated
a larger AM:PM ratio. Transformation of the MMSE errors
normalized the distribution to be suﬃciently appropriate for
the analysis (mean 0.87, median 0.69, kurtosis 2.62, skewness
0.08; ﬁgure e-1, doi.org/10.5061/dryad.vb3g6p1). Greater
educational attainment was obtained by men in both cohorts
while hypertension and greater BMI was more prevalent in
men in the Whitehall II cohort. The mean and SD for each
cognitive outcome and cortisol measure and prevalence are
described in table 1. The interaction term between AM:PM
ratio and sex did not reveal sex betweenMMSE errors and AM:
PM ratio (p = 0.770), CAR (p = 0.902), or area under the curve
(AUC) (p = 0.455), or between ﬂuency and AM:PM ratio (p =
0.411), CAR (p = 0.880), or AUC (p = 0.223).
There was an association between AM:PM ratio and subsequent
cognitive function in univariate (table 2) analyses (0.03 fewer
MMSE errors per SD increase in AM:PM ratio per year, 95% CI
0.02 errors to 0.04 errors, p < 0.01), which remained when
fully adjusted (0.02 fewer MMSE errors per SD increase in
AM:PM ratio, 95% CI 0.00–0.03, p = 0.01) (table 3). An as-
sociation between AM:PM ratio and verbal ﬂuency was also
evident (0.06 SD increase in verbal ﬂuency per SD increase in
AM:PM ratio, 95% CI 0.04–0.08, p < 0.01), which remained on
full adjustment (0.03 SD increase in verbal ﬂuency per SD
increase in AM:PM ratio, 95% CI 0.01–0.05, p < 0.01). In-
creasing age, male sex, greater educational attainment, in-
creased BMI, and diagnoses of hypertension and diabetes
were also associated with poorer later-life cognitive function.
An association between depression caseness and later-life
cognition attenuated on full adjustment (95% CI −0.05 to
0.01, p = 0.17).
No associations were found between CAR and subsequent
MMSE errors or verbal ﬂuency in univariate or fully adjusted
models. Increasing age, lower educational attainment, di-
agnosis of hypertension, diagnosis of diabetes, increased BMI,
and increased delay between cortisol measurement and cog-
nitive assessment were all associated with worse cognitive
function (table 3). Each was also associated with poorer verbal
ﬂuency (except follow-up interval). Overall, no prospective
associations between cognitive function and subsequent
cortisol were evident.
Finally, in considering contribution of baseline cognitive
function, corresponding and directly comparable cognitive
assessments at baseline was only available for the Whitehall II
participants (table e-4, doi.org/10.5061/dryad.vb3g6p1). In
further multivariate analyses within the Whitehall subset, the
prospective association between cortisol diurnal variation and
later-life cognitive performance persisted even when baseline
cognitive performance was adjusted for (table e-4, doi.org/10.
5061/dryad.vb3g6p1). For verbal ﬂuency, the association was
attenuated on adjustment for performance in the prior data
collection wave (table e-4, doi.org/10.5061/dryad.vb3g6p1).
Between measures of cortisol within each analysis, approxi-
mately 69% of the harmonized cohorts had complete meas-
ures of cortisol measures, later-life cognitive outcomes, and all
covariates. All models were repeated using multiple imputa-
tion data to account for missing covariates, the ﬁndings of
which did not diﬀer from the main analyses (table e-3, doi.
org/10.5061/dryad.vb3g6p1).
Discussion
In our longitudinal cross-cohort study, decreased AM:PM corti-
sol ratio was prospectively associated with small impairments in
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Table 1 Participant characteristics of Whitehall II 2002–2004 and 2007–2009 and National Survey for Health and Development (NSHD) 2006–2010
Whitehall II 2002–2004 Whitehall II 2007–2009 NSHD
No. Men No. Women p Value No. Men No. Women p Value No. Men No. Women p Value
30-Point global
cognition
4,434 28.7 (1.2) 1842 28.6 (1.9) <0.01 3,745 28.5 (1.2) 1,398 28.5 (1.4) 0.244 858 26.0 (2.9) 916 26.6 (2.8) <0.01
Cortisol awakening
responsea
2,685 6.76 (9.06) 949 8.31 (9.55) <0.01 3,016 5.83 (8.74) 1,151 7.13 (9.11) <0.01 1,376 4.83 (9.72) 1,598 7.25 (9.62) <0.01
AM:PM ratioa 2,591 12.2 (10.0) 941 10.8 (8.83) <0.01 2,877 8.96 (6.39) 1,132 7.95 (5.64) <0.01 478 9.46 (5.64) 539 8.24 (4.97) <0.01
Agea 4,591 61.0 (5.93) 1892 61.4 (6.05) 0.01 4,445 65.8 (5.88) 1780 66.1 (6.03) 0.05 1,067 63.3 (1.15) 1,161 63.4 (1.08) 0.03
Educational
attainment
3,310 1,307 1,009 1,102
<O levels 25.60% 40.40% 38.50% 40.40%
O level 25.10% 24.70% 14.80% 26.60%
≥A levels 49.40% 34.90% <0.01 46.80% 33.00% <0.01
Hypertension 4,430 37.74% 1770 35.76% <0.01 1,063 41.58% 1,151 35.71% <0.01
Diabetes 4,445 8.01% 1780 9.44% 0.07 1,181 8.76% 1,280 6.64% 0.05
BMIa 4,424 26.6 (4.0) 1769 27.3 (5.6) <0.01 1,061 27.9 (4.1) 1,158 27.9 (5.5) 0.92
Depression “case” 4,651 13.87% 1924 18.70% <0.01 1,051 13.04% 1,139 22.04% <0.01
Abbreviation: BMI = body mass index.
a Mean (SD) listed for cortisol awakening response, AM:PM ratio, age, and BMI.
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later-life cognition and subsequently decreased verbal ﬂuency
following adjustment for age, sex, educational attainment, hy-
pertension, diabetes, BMI, and depression. No prospective
association was found between CAR and cognitive function at
follow-up. No reverse associations were found between cog-
nition and later-life cortisol measures. Taken together, these
ﬁndings suggest blunted HPAA diurnal variation precedes and
may contribute to increased risk of later-life cognitive decline in
the general population.
These results should be interpreted in the context of strengths
and weaknesses of the study design. A main strength was the
large sample size made possible by integration of 2 longitu-
dinal cohorts with harmonized exposures, outcomes, and
a long history of collaboration, harmonization, and partici-
pation in consortia.26 Second, the 5- and 9-year period from
cortisol measurement to cognitive assessment allowed longer-
term outcomes to be ascertained. Multiple cortisol sample
collections over 24 hours allowed for accurate proﬁling of
HPAA activity. Finally, cortisol collection from saliva instead
of serum11 minimized acute stress response caused by veni-
puncture while measuring free, unbound cortisol.
Nonetheless, challenges in cortisol collection were evident
from the amount of missing data in both cohorts, and this is
likely to be missing-not-at-random. For example, individuals
with lower cognitive measures are less likely to have complete
24-hour cortisol proﬁles, introducing potential source of se-
lection bias in our complete case approach. However, esti-
mating these models again using multiple imputation did not
produce diﬀerent conclusions (table e-3, doi.org/10.5061/
dryad.vb3g6p1). In addition, while the 2 cohorts are compa-
rable in most respects, the exact collection schedule for salivary
cortisol diﬀered (6 times/24 hours in Whitehall II; 4 times/24
hours in NSHD). As a result, while AUC would have been the
optimal method to characterize cortisol proﬁling, AUC calcu-
lation would have been more accurate for Whitehall II com-
pared to NSHD. AM:PM ratio was chosen as a measure of
diurnal blunting instead to utilize 2 directly comparable col-
lection points. In addition, cohort-speciﬁc estimates were af-
fected through diﬀerences in data collection. Baseline cognition
was only available in Whitehall II participants, while other
speciﬁc cognitive domains were only repeated in NSHD par-
ticipants. An association between diurnal variation and later-life
cognition was still evident inWhitehall II participants adjusting
for baseline cognition, and coeﬃcient directions for search
speed and verbal memory were consistent (though un-
derpowered) in NSHD participants (tables e-6 and e-7, doi.
org/10.5061/dryad.vb3g6p1). In common with other cohort
studies, our ﬁndings may be subject to residual confounding
and are speciﬁc to the population and era under study. Finally,
translation of our ﬁndings into diagnoses of dementia was not
possible due to the relatively low number of clinical cases in this
age range. However, cognitive impairment as demonstrated by
Table 2 Univariate prospective associations between Mini-Mental State Examination (MMSE) errors and fluency scores
(per SD) with lagged cortisol measures in maximum sample
Univariate
MMSE errors Fluency (per SD)
No. Coefficient 95% CI p Value No. Coefficient 95% CI p Value
CAR (per SD) 7,994 −0.01 −0.02 to 0.00 0.21 8,072 0.02 0.00 to 0.04 0.11
AM:PM ratio (per SD) 7,427 −0.03 −0.04 to −0.02 <0.01 7,459 0.06 0.04 to 0.08 <0.01
Age 20,148 0.02 0.02 to 0.02 <0.01 25,660 −0.02 −0.03 to −0.02 <0.01
Sex 13,307 0.07 0.04 to 0.09 <0.01 25,987 −0.10 −0.14 to −0.06 <0.01
Educational attainment 15,987 19,669
<O levels Ref
O level −0.16 −0.18 to −0.13 Ref 0.34 to 0.44 <0.01
≥A levels −0.20 −0.22 to −0.18 <0.01 0.57 0.52 to 0.62 <0.01
Cohort 21,122 −0.42 −0.44 to −0.40 <0.01 25,987 0.00 −0.05 to 0.05 0.99
Time of cortisol to cognitive
ascertainment (year)
11,761 0.15 0.13 to 0.16 <0.01 12,726 0.00 −0.02 to 0.02 0.97
Hypertension 19,514 0.12 0.10 to 0.14 <0.01 23,648 −0.23 −0.27 to −0.19 <0.01
Diabetes 19,815 0.15 0.10 to 0.19 <0.01 23,730 −0.36 −0.44 to −0.29 <0.01
BMI (per SD) 19,516 0.02 0.01 to 0.03 <0.01 23,651 −0.05 −0.07 to −0.03 <0.01
Depression “case” 19,577 0.05 0.02 to 0.08 0.02 23,797 −0.06 −0.12 to −0.01 0.02
Abbreviations: BMI = body mass index; CAR = cortisol awakening response; CI = confidence interval.
Results clustered for each study participant.
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MMSE and ACE-III in Whitehall II and NSHD were un-
common at the ages we examined: while not a deﬁnition for
dementia, MMSE scores under 24 were found in only 0.48%, 0.
78%, and 1.84% for Whitehall II waves 7, 9, and 11, re-
spectively; and ACE-III scores of under 82 in 6.5% of NSHD
participants at age 69.
While there are relatively few studies of similar size for com-
parison, our ﬁnding that HPAA dysfunction is associated with
later-life cognitive impairment is in keeping with ﬁndings of the
Baltimore Longitudinal Study of Aging and the Longitudinal
Aging Study of Amsterdam, which reported increased diurnal
variation and random cortisol levels in similarly aged older
Table 3 Prospective associations between cognitive measures (Mini-Mental State Examination [MMSE] errors and
fluency scores per SD) with lagged cortisol measures from previous wave in fully adjusted models
Fully adjusted
MMSE errors (n = 5,982) Fluency per SD (n = 5,951)
Coefficient 95% CI p Value Coefficient 95% CI p Value
CAR (per SD) −0.01 −0.02 to 0.01 0.27 0.01 −0.01 to 0.03 0.23
Age 0.02 0.01 to 0.02 <0.01 −0.04 −0.04 to −0.04 <0.01
Sex −0.05 −0.08 to −0.02 0.01 0.04 −0.02 to 0.10 0.17
Educational attainment
<O levels Ref Ref
O level −0.12 −0.15 to −0.08 0.31 0.24 to 0.37
≥A levels −0.16 −0.19 to −0.13 <0.01 0.46 0.40 to 0.52 <0.01
Cohort −0.38 −0.41 to −0.35 <0.01 −0.20 −0.29 to −0.11 <0.01
Time of cortisol to
cognitive
ascertainment
0.05 0.02 to 0.07 <0.01 −0.09 −0.13 to −0.06 <0.01
Hypertension 0.03 0.00 to 0.06 0.04 −0.05 −0.11 to 0.00 0.07
Diabetes 0.10 0.03 to 0.17 0.01 −0.23 −0.33 to −0.12 <0.01
BMI (per SD) 0.04 0.01 to 0.07 <0.01 −0.02 −0.05 to 0.01 0.15
Depression “case” −0.02 −0.05 to 0.01 0.17 −0.08 −0.16 to −0.01 0.03
Fully adjusted
MMSE errors (n = 5,511) Fluency per SD (n = 5,747)
Coefficient 95% CI p Value Coefficient 95% CI p Value
AM:PM ratio (per SD) −0.02 −0.03 to 0.00 0.01 0.03 0.01 to 0.05 <0.01
Age 0.02 0.01 to 0.02 <0.01 −0.04 −0.04 to −0.03 <0.01
Sex −0.05 −0.08 to −0.02 0.01 0.05 −0.01 to 0.11 0.09
Educational attainment
<O levels Ref Ref
O level −0.11 −0.15 to −0.07 0.34 0.27 to 0.40
≥A levels −0.14 −0.18 to −0.11 <0.01 0.48 0.42 to 0.54 <0.01
Cohort −0.38 −0.41 to −0.34 <0.01 −0.10 −0.19 to −0.01 0.02
Time of cortisol to
cognitive
ascertainment
0.04 0.02 to 0.07 <0.01 −0.07 −0.11 to −0.04 <0.01
Hypertension 0.03 −0.01 to 0.07 0.10 −0.06 −0.12 to −0.01 0.03
Diabetes 0.09 0.02 to 0.17 0.01 −0.20 −0.31 to −0.09 <0.01
BMI (per SD) 0.04 0.01 to 0.08 0.02 −0.02 −0.05 to 0.01 0.14
Depression “case” −0.03 −0.06 to 0.01 0.13 −0.08 −0.16 to −0.01 0.04
Abbreviations: BMI = body mass index; CAR = cortisol awakening response; CI = confidence interval.
Results clustered for each study participant.
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adults to be associated prospectively with impaired cognitive
function and Alzheimer disease risk, respectively.11,27 In addi-
tion, HPAA dysfunction had also been previously associated
with prospective cognitive decline in cognitively healthy adults
with positive β-amyloid on PET scans, suggesting that HPAA
dysfunction may be a marker of, share, or even mediate path-
ogenic β-amyloid mechanisms in cognitive impairment that
may represent early preclinical phases of Alzheimer disease.28
Our ﬁndings also suggest an association between HPAA dys-
function and cognition only becomes evident at older ages,27 in
keeping with a sensitive period for cognitive decline.29 Similar
associations were not present at younger ages from both con-
stituent cohorts: there were no prospective associations be-
tween cortisol proﬁles at 2002–2004 and cognitive assessments
at 2007–2009 in Whitehall II12; there were no cross-sectional
associations between cortisol diurnal variation and cognitive
measures at ages 60–64 in NSHD participants.22
The speciﬁc association of AM:PM ratio with later-life cognition
highlights the signiﬁcance of blunted HPAA diurnal variation.
Although the demonstrated eﬀect sizes appear small, even small
per year individual eﬀects may have cumulative eﬀect when
considered at a population level, particularly when cognitive
decline may subclinically progress over decades. Second, the
ﬁnding suggests an additional mechanism apparently contrib-
uting to cognitive aging in the population, above more estab-
lished risk factors such as diabetes and hypertension. This
implicates HPAA dysfunction as a potential pathogenic factor
towards later-life cognitive impairment, providing a possible
novel target for future research and potential therapeutic tar-
gets. On a cellular level, blunted diurnal variation is associated
with reduced synaptic plasticity.14 In addition, blunted diurnal
variation is hypothesized to indicate reduced capacity to adapt
during aging and changes in cardiovascular proﬁle.15,30 Con-
sequently, reactions from endocrine, immune, and cardiovas-
cular systems may be initiated or ampliﬁed to environmental
and psychosocial stressors, contributing to negative health
consequences such as dementia.31 The lack of prospective
association between CAR and cognition in our study may
indicate a more nuanced role for CAR that is diﬃcult to
ascertain given data limitations within our study. Although
associated with spatial memory,32 CAR is thought to antic-
ipate cognitive demands by taking into account previous
experiences,13 hence its absence in patients with retrograde
amnesia,33 after waking from a nap,34 and when waking in
the middle of the night.35 Such a role for CAR is anatomi-
cally plausible, given hippocampal inputs to the hypothala-
mus and the function of the hippocampus to provide
a cohesive construct and representation of the outside world
by processing relationships with time, space, and environ-
mental cues.
Given that a blunted HPAA diurnal proﬁle may provide
a physiologic substrate for incipient cognitive decline in the
population, HPAAdysfunction could oﬀer a potential target for
disease modiﬁcation in dementia. Selective inhibition of 11-
β-hydroxysteroid dehydrogenase-1, an enzyme selectively
expressed in human hippocampus, cerebellum, and frontal
cortex, that regenerates glucocorticoid from circulating corti-
sone, amplifying intracellular glucocorticoid concentrations,
has been associated with improved verbal ﬂuency in healthy
older men, and verbal memory in type 2 diabetic older men.36
Overall, the relationship between HPAA and cognition is
complex; nonetheless, our ﬁndings support loss of diurnal
HPAA variation as an early marker of later-life cognitive im-
pairment and a potential future target for disease modiﬁcation.
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